THORAZINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Nov 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THORAZINE (chlorpromazine) is an oral tablet small-molecule antipsychotic approved in 1957, representing a landmark first-generation antipsychotic. The exact indications are not specified in available data, but historically it has been used for psychotic disorders, severe behavioral disturbances, and other psychiatric conditions. Mechanism of action involves dopamine antagonism in the central nervous system.
LOE Approaching
LOE-approaching lifecycle indicates contracting commercial footprint; brand team focus is likely defensive maintenance rather than growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THORAZINE offers limited career advancement potential due to its LOE-approaching status and lack of active linked job openings. Roles on this product focus on managing decline and compliance rather than growth, development, or innovation.
Product ManagerField Sales Representative
Worked on THORAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.